Mirum Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-67.2M | $-790.2M | $-5.7M | $2.9M | $-5.9M | $-14.7M | $-23.8M | $-14.2M |
| Depreciation & Amortization | $6.9M | $6.9M | $6.1M | $6.1M | $6.1M | $6.1M | $6.1M | $6.1M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | $6.7M | $6.8M | $6.0M | $6.0M | $5.9M | $6.0M | $6.0M | $5.9M |
| Stock-Based Compensation | $30.6M | $36.2M | $19.0M | $18.1M | $18.5M | $15.8M | $13.3M | $11.9M |
| Net Cash from Operating Activities | $-44.3M | $-228.8M | $6.1M | $39.7M | $12.0M | $-2.0M | $-5.1M | $4.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $23.0K | $664.0K | $600.0K | $187.0K | $126.0K | $41.0K | $20.0K | $181.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-160.0M | $-11.6M | $1.0M | $-2.2M | $-6.6M | $-16.1M | $641.0K | $-18.0M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $211.4M | $270.1M | $9.0M | $16.1M | $8.7M | $6.4M | $5.3M | $3.9M |
| Net Change in Cash | $5.8M | $28.5M | $15.7M | $53.9M | $16.4M | $-10.7M | $-466.0K | $-10.1M |
| Free Cash Flow | $-44.3M | $-229.4M | $5.5M | $39.5M | $11.9M | $-2.0M | $-5.1M | $3.8M |